• Dicembre 2024 – Collaborazione tra AIFA, AIOM, CIPOMO e FICOG, per lo sviluppo scientifico dei dati contenuti nel Registro di Monitoraggio di pazopanib per il trattamento del sarcoma dei tessuti molli. Sulla rivista ESMO Open è disponibile la pubblicazione dal titolo: “Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry”. L’analisi statistica ha riguardato una coorte di pazienti affetti da sarcoma dei tessuti molli. L’obiettivo dell’analisi era quello di caratterizzare i pazienti trattati con pazopanib nella pratica clinica e verificare l’associazione tra tempo alla discontinuazione e sottotipo istologico.

Recent observational studies from Pubmed (limit 1 year, medication adherence OR persistence)

• Palbociclib
• Ribociclib
• Abemaciclib

• Alectinib
• Lorlatinib
• Brigatinib

• Atezolizumab
• Durvalumab

Palbociclib

• Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
  August 11, 2026 by E Carola
• The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
  March 27, 2026 by Ahmet Oruç
• Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America
  March 19, 2026 by Cynthia Villarreal-Garza
• Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study
  February 26, 2026 by Daniel Rayson
• The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors
  January 28, 2026 by Alexandra Paulet

Ribociclib

• The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
  March 27, 2026 by Ahmet Oruç
• Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America
  March 19, 2026 by Cynthia Villarreal-Garza
• The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors
  January 28, 2026 by Alexandra Paulet
• Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
  November 29, 2025 by Onur Baş
• Assessing the Influence of Proton Pump Inhibitors on Clinical Outcomes in Hormone Receptor-Positive Metastatic Breast Cancer Patients Receiving CDK4/6 Inhibitors: Evidence from a Ribociclib-Dominant Cohort
  November 27, 2025 by Enes Erul

Abemaciclib

• Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study
  September 2, 2026 by Carl Rosander
• Real-World Safety Profile of Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer
  August 27, 2026 by Maria Pimenta Macedo
• Prescribing patterns and real-world clinical usage of adjuvant abemaciclib for early-stage, high-risk, hormone receptor-positive breast cancer
  July 2, 2026 by Sneha Rajendran
• Real-world data on patients with HR+, HER2- early breast cancer prescribed with abemaciclib adjuvant therapy for 2 years in Japan
  June 8, 2026 by Yukinori Ozaki
• Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
  April 7, 2026 by Noor Lad

top page

Alectinib

• Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population
  June 24, 2026 by Khalil Choucair
• Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study
  December 10, 2025 by Haoran Zhang

Lorlatinib

• Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population
  June 24, 2026 by Khalil Choucair

Brigatinib

top page

Atezolizumab

• Real-world treatment persistence of first-line atezolizumab in elderly patients with PD-L1-high NSCLC: comparison with pembrolizumab
  September 1, 2026 by Tomohiro Oba
• Early lenvatinib dose intensity is associated with survival in super-older adults ( 80 years) with hepatocellular carcinoma: a real-world comparison with atezolizumab-bevacizumab
  August 28, 2026 by Masamichi Kimura
• Baseline Lymphopenia Predicts Survival in ICI-Naive Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis
  June 26, 2026 by Ahmed Ismail
• Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study
  May 6, 2026 by Kaho Aoe
• Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab
  February 27, 2026 by Hisanori Muto

Durvalumab

• Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy
  August 12, 2026 by Jiayi Yu
• Exploring social determinants of health and immunotherapy utilization in patients with stage III non-small-cell lung cancer after definitive chemoradiation
  August 9, 2026 by C Hwang
• Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC
  July 30, 2026 by May-Lucie Meyer
• Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population
  July 26, 2026 by Adam L Peters
• Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study
  May 19, 2026 by Nobuyuki Yamamoto

top page